glp-1 obesity drug news today 2025 Market Outlook for obesity in 2025:

Evidence is emerging that glucagon-like peptide-1 (GLP-1) receptor agonists have anti-inflammatory and chondroprotective properties independent of their effects on weight loss

Retatrutide vs Semaglutide: Evidence-based comparison of the investigational triple GIP/GLP-1/glucagon agonist versus the FDA-approved GLP-1 agonist

Obesity is a complex disease, excessive fat accumulation caused by genetic, environmental and other factors, that has seen the most rapid growth in terms of ...

They now cost about Rs 1,0002,500 a month, and there's growing evidence pointing to benefits well beyond weight loss, including cardiovascular, metabolic, and liver health

There 9 types of antidiabetic drugs, of which GLP-1RAs are the most popular, find the evolution of GLP-1RAs and their challenges and solutions,

A newly published clinical investigation in the British Journal of Anaesthesia (May 2025 issue) reveals compelling evidence linking glucagon-like peptide-1 receptor agonists (GLP-1RAs) to impaired gastric emptying (IGE)